September 15, 2009 – Elekta reported net sales increased by 15 percent, profit after taxes increased to SEK 56 million, and earnings per share after dilution were up to SEK 0.62 in the first three months of 2009/2010.

Demand for Elekta’s clinical solutions, products and services remained strong in. Order bookings rose by 19 percent in local currency with solid performance in all regions. Net sales grew to SEK 1,440 M and operating result rose to SEK 89 M. Earnings per share improved to SEK 0.62 from SEK 0.02.

Demand increased for aftermarket services and software. Elekta provides services dur-ing the lifetime of the product and software for efficient workflow solutions, thereby making it possible for customers to focus on patient care. We continue to grow with our over 5,000 customers - an important element for Elekta’s sustainable profitable growth.

Elekta is a leading provider of image guided radiotherapy, stereotactic radiotherapy and radiosurgery and oncology software. This year we are increasing investments in re-search and development to bring new and refined solutions to market for improved patient care and higher efficiency for healthcare providers.

At the end of July Elekta received FDA-clearance for VMAT in combination with the radiation treatment planning system Monaco. This is expected to lead to growing sales of VMAT towards the end of this year.

We are continuing to execute on our plan for geographical expansion. With a complete portfolio of products and solutions fulfilling the clinical demands, Elekta is in a strong position for future growth from new territories. In the quarter Elekta has added new partners offering financing solutions by signing agreements with Swedish Export Corporation, SEK, and Swedfund International AB. The aim is to improve availability for cancer care worldwide, and to seize the opportunities of growth for Elekta.

The economic downturn has so far had limited effect on investments in cancer care, but the uncertainty remains. It may become more difficult for private customers to obtain financing and future health care investments might be negatively affected.

Elekta’s efficiency improvement program is proceeding according to plan. Restructuring costs amounted to SEK 11 M in the quarter. Annual savings from the program are expected at SEK 100 M with full effect next fiscal year. For 2009/10 the operating costs are expected to increase by around 5 percent in local currency.

Currency markets remained volatile in the quarter. We expect positive effect on results for this fiscal year at close to SEK 250 M at present currency rates.

Elekta’s financial outlook remains unchanged of an increase in net sales by more than 8 percent in local currency, and operating profit increase in kronor of more than 35 percent. Net sales and operating profit are expected to be significantly higher in the second half of the year compared with the first.

For more information: www.elekta.com

Related Content

News | Proton Therapy

June 24, 2021 — Mevion Medical Systems announced that the first proton center in the Mountain West, the Senator Orrin G ...

Time June 24, 2021
arrow
News | Linear Accelerators

June 18, 2021 — Elekta announced that its Elekta Harmony radiation therapy system recently received U.S. FDA 510(k) ...

Time June 18, 2021
arrow
News | Linear Accelerators

January 20, 2021 — A joint team of researchers from Radiation Oncology at Dartmouth's and Dartmouth-Hitchcock's Norris ...

Time January 20, 2021
arrow
News | Linear Accelerators

January 4, 2021 — RAD Technology Medical Systems (RAD) announced it is expanding its portfolio of patented modular ...

Time January 04, 2021
arrow
News | Radiation Oncology

April 17, 2020 — PTW has installed the first Beamscan MR motorized 3-D water phantom in North America at the Princess ...

Time April 17, 2020
arrow
News | Radiation Oncology

January 30, 2020 — Elekta announced that it signed a contract with the Institut Jules Bordet, Brussels, for an Elekta ...

Time January 30, 2020
arrow
Technology | Quality Assurance (QA)

IBA Dosimetry GmbH announced the launch of the new enhanced myQA Machines 2019 software environment at the upcoming American Society for Radiation Oncology (ASTRO) congress, Sept. 15-19 in Chicago.

Time September 12, 2019
arrow
Videos

Kristin Higgins, M.D., medical director of radiation oncology at the Emory Clinic at the Winship Cancer Institute, and ...

Time October 29, 2018
arrow
News | Radiation Therapy

Gustave Roussy has awarded Elekta with an order for four Versa HD linear accelerators, replacing their existing installed base of competing systems. The premier European comprehensive cancer center started its radiotherapy program in 2013.

Time September 04, 2015
arrow
News

The ECRI Institute released a new techIQ brief on key factors to consider when purchasing a linear accelerator (linac) for external beam radiation therapy. The report is a compilation of results from a survey of hundreds of users of linac-based radiosurgery systems; participants were asked to rate the functions and features of the four major linac vendors: Accuray, Brainlab, Elekta and Varian Medical Systems.

Time June 23, 2015
arrow
Subscribe Now